Skip Nav Destination
Drug Discovery
Ion Channel Drug Discovery
Edited by
Martin Gosling
Martin Gosling
Novartis, UK
Search for other works by this author on:
Hardback ISBN:
978-1-84973-186-7
PDF ISBN:
978-1-84973-508-7
EPUB ISBN:
978-1-78262-307-6
Special Collection:
2014 ebook collection
,
2011-2015 industrial and pharmaceutical chemistry subject collection
Series:
Drug Discovery
No. of Pages:
384
Publication date:
03 Sep 2014
Book Chapter
CHAPTER 10: Open Access to the KCNQ Channel: Retigabine and Second Generation M-current Openers
By
Johannes Krupp
;
Johannes Krupp
AstraZeneca R&D
Södertälje
Sweden
Search for other works by this author on:
Anthony M. Rush
;
Anthony M. Rush
AstraZeneca R&D
Södertälje
Sweden
Search for other works by this author on:
Britt-Marie Swahn
;
Britt-Marie Swahn
AstraZeneca R&D
Södertälje
Sweden
Search for other works by this author on:
Martin Main
Martin Main
Search for other works by this author on:
-
Published:03 Sep 2014
-
Special Collection: 2014 ebook collection , 2011-2015 industrial and pharmaceutical chemistry subject collectionSeries: Drug Discovery
Page range:
238 - 257
Citation
J. Krupp, A. M. Rush, B. Swahn, and M. Main, in Ion Channel Drug Discovery, ed. B. Cox and M. Gosling, The Royal Society of Chemistry, 2014, pp. 238-257.
Download citation file:
In 2011, Retigabine (Ezogabine; Valeant Pharmaceuticals/GlaxoSmithKline), an opener of KCNQ (Kv7) potassium channels, was approved for the adjunctive treatment of partial-onset seizures in adult patients. In this chapter, we review the story of retigabine, from identification as a novel anticonvulsant through to clinical testing, and detail the ongoing work to identify a second generation of KCNQ channel openers.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Digital access
$64.60
